ĀÜĄņĀŅĀ×

Gerhard Gross has extensive work experience in the pharmaceutical industry. Gerhard is currently a Senior Scientific Advisor at NAIAD Drug Design, where they provide scientific guidance. Gerhard also owns GG Pharma Consultancy, which they established in 2020.

Prior to their current roles, Gerhard served as the Chief Scientific Officer at Pannex Therapeutics, where they pioneered the development of a new therapeutic class for the treatment of chronic pain and opioid addiction. At Biozeus, they worked as a Development Leader, contributing to the company's projects from 2017 to 2020.

Gerhard has also held various positions at Janssen, Pharmaceutical Companies of Johnson and Johnson. Gerhard initially worked as a PDM Project Representative in the discovery for oncology projects, ensuring the coordination and evaluation of DxDMPK support. Later, they became the Scientific Director and the Head of Early Drug Developability.

In addition, Gerhard has worked as a Scientific Advisor at EntomoPharm and a Guest Lecturer at the University of Copenhagen. Gerhard served as the Head of Drug Metabolism at Lundbeck and the Global Discipline Leader ADME and Section Director Metabolism at AstraZeneca. In these roles, they provided scientific leadership and strategic direction to the organizations.

Overall, Gerhard Gross has a strong background in scientific expertise, leadership, and consultancy in the pharmaceutical industry.

Gerhard Gross completed their Bachelor's degree in Chemistry and Physics at The Philipp University of Marburg from 1975 to 1978. Gerhard then pursued a Master's degree in Chemistry and Physics at the same university from 1978 to 1980. After that, they enrolled in The Philipp University of Marburg once again to pursue a PhD in Organic Chemistry from 1980 to 1983. Following the completion of their PhD, Gerhard Gross went on to do a Postdoctoral fellowship in Physical Chemistry at the University of Utah from 1983 to 1985.